에 대한 최신 뉴스 Nutex Health (NASDAQ:NUTX) 주식

Nutex Health

Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.

Market Recovery image

Opinion

Trading Ideas

ACHR

HNRG

NUTX

RGTI

RKLB

VNET

오늘은 유망한 기술적 추세가 주가 상승을 이끌고 있는 6가지 종목을 살펴보려고 한다. 벤징가 엣지에서 모멘텀 점수가 최소 98점 이상인 종목 중 향후 몇 주 동안 상승할 가능성이 있는 종목에 초점을 맞추고 있다.

미국 증시 반등 속 기술적 모멘텀 보이는 주식 6종목

Nutex Health Inc

Prominent short seller Jim Chanos criticized Tesla Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) robotaxi economic projections on Monday, calling the figures &#8220;ridiculous&#8221; and pointing to several overlooked cost factors.
What Happened: Chanos, responding to a Tesla investor&#8217;s profit calculations on X, highlighted that &#8220;roughly half of all ride-hailing miles are &#8216;dead&#8217; (non-revenue) miles.&#8221; He also noted commercial auto insurance costs &#8220;3- 4x personal auto insurance&#8221; at approximately &#8220;30-40 cents per mile,&#8221; with additional expenses for cleaning at $400 per month.
Chanos argued that the major cost for a Robotaxi fleet would be redundancy, safety, and monitoring, which the Massachusetts Institute of Technology has estimated could range from $0.05 to $2.35 per mile, depending on regulations. He also questioned the viability of Tesla&#8217;s projections by pointing out that the entire U.S. taxi and ridesharing market is expected to be valued at $50 billion to $75 billion in 2024.
When challenged about potential higher revenue, Chanos expressed doubt, citing consumers&#8217; ability to &#8220;operate their own vehicles at a marginal cost of 50-60 cents per mile&#8221; and noting that &#8220;commoditized service markets tend to converge revenues to marginal cost.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">These figures are, of course, ridiculous. First of all, roughly half of all ride-hailing miles are "dead" (non-revenue) miles. Second, commercial auto insurance is 3-4x personal auto insurance(10 cents per mile), or 30-40 cents per mile. Cleaning costs($400/month), etc. <a href="https://t.co/t5HJVooUsi">https://t.co/t5HJVooUsi</a>
&mdash; James Chanos (@RealJimChanos) <a href="https://twitter.com/RealJimChanos/status/1917029597574529280?ref_src=twsrc%5Etfw">April 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/personal-finance/25/04/45056962/bill-gates-says-hes-happier-as-a-billionaire-than-if-he-were-middle-class-you-dont-need-a-billionbut-freedom-from-worry-is-a-blessing">Bill Gates Says He&#8217;s Happier As A Billionaire Than If He Were Middle Class — &#8216;You Don&#8217;t Need A Billion…But Freedom From Worry Is A Blessing&#8217;</a>
Why It Matters: Tesla has been preparing for its limited robotaxi launch in Austin this June, with CEO Elon Musk announcing plans to deploy only 10-20 vehicles initially. The company has <a href="https://www.benzinga.com/tech/25/04/44972108/tesla-quietly-launched-robotaxi-service-for-employees-before-june-debut-now-reports-1500-completed-trips">already launched an employee-only autonomous ride-hailing service</a> in Austin and San Francisco, completing over 1,500 trips covering 15,000 miles.
Investor Gary Black recently described the upcoming launch as &#8220;an experiment&#8221; rather than a true market test, citing the limited deployment and &#8220;asymmetry of risks.&#8221; Former Waymo CEO John Krafcik has also questioned Tesla&#8217;s <a href="https://www.benzinga.com/markets/25/04/44979720/teslas-robotaxi-launch-in-june-will-likely-be-a-non-event-says-gary-black-this-isnt-really-a-test-market-its-an-experiment">readiness for autonomous taxi operations</a>.
Despite skepticism, Tesla has intensified testing efforts with approximately 300 drivers in Austin under &#8220;Project Rodeo,&#8221; while collaborating with local emergency services and developing its robotaxi app for the <a href="https://www.benzinga.com/tech/25/04/45028007/tesla-prepares-for-robotaxi-reveal-in-june-insiders-share-secrets">planned June 1 launch</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/45056965/dave-ramsey-says-doctors-and-lawyers-are-like-actors-notoriously-bad-with-money-just-because-you-make-a-lot-doesnt-mean-youre-winning">Dave Ramsey Says Doctors And Lawyers Are Like Actors, Notoriously Bad With Money — &#8216;Just Because You Make A Lot Doesn&#8217;t Mean You&#8217;re Winning&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Equities

News

Short Sellers

Markets

TSLA

Short Seller Jim Chanos Slams Tesla Robotaxi Economics As 'Ridiculous,' Citing Dead Miles, Insurance Costs And Cleaning Expenses

Leerink Partners analyst Puneet Souda downgrades Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) from Outperform to Market Perform and lowers the price target from $12 to $8.

Downgrades

Price Target

Analyst Ratings

QTRX

Leerink Partners Downgrades Quanterix to Market Perform, Lowers Price Target to $8

Earnings

GRMN

Garmin Q1 Gross Margin 57.6% vs 58.1% YoY

SPWR

SunPower Formerly Complete Solaria Reports Q1 Revenues Of $88.674M, Company Finished Q1 With $14M In Cash Vs. $13.3M In Q4

First Foundation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NYSE">FFWM</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.03 by 200 percent. This is a 350 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $71.40 million which beat the analyst consensus estimate of $64.19 million by 11.24 percent. This is a 39.81 percent increase over sales of $51.07 million the same period last year.

Earnings Beats

FFWM

First Foundation Q1 Adj. EPS $0.09 Beats $0.03 Estimate, Sales $71.40M Beat $64.19M Estimate

Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.42) by 9.52 percent. This is a 70.37 percent decrease over losses of $(0.27) per share from the same period last year.

Earnings Misses

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics Q1 EPS $(0.46) Misses $(0.42) Estimate

Needham analyst Kyle Peterson reiterates Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Buy and maintains $2500 price target.

Reiteration

FICO

Needham Reiterates Buy on Fair Isaac, Maintains $2500 Price Target

DTCK

Davis Commodities Forms Strategic Joint Venture With Malaysian Agri-Processor To Tap ASEAN FTA Benefits And Secure Key Market Access

EXTR

Extreme Networks Q3 2025 Adj. EPS $0.21 Beats $0.18 Estimate, Sales $284.50M Beat $280.32M Estimate

USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) (USAR or the Company), today announced that it has entered into a securities purchase agreement with a new fundamental institutional investor to raise $75 million of equity capital via a private investment in public equity ("PIPE"). The Company intends to use the proceeds from the offering to fund capital expenditures for its magnet manufacturing facility in Stillwater, Oklahoma, as well as for working capital and operating expenses.
Under the terms of the securities purchase agreement, the Company will issue, for an aggregate purchase price of $75 million, an aggregate of approximately 8.55 million shares of common stock (the Issued Shares), pre-funded warrants to purchase an aggregate of approximately 2.16 million shares of common stock (the shares underlying the Pre-Funded Warrants, together with the Issued Shares, "the Aggregate Shares") and warrants (the PIPE Warrants) to purchase shares of common stock, in an amount equal to 100% of the Aggregate Shares at a strike price of $7.00 per share, with an expiry date of 6-years from the issue date of the PIPE Warrants. The Shares and the PIPE Warrant Shares are entitled to customary resale registration rights.
 &nbsp;

USAR

USA Rare Earth Enters Into Securities Purchase Agreement With New Fundamental Institutional Investor To Raise $75M Of Equity Capital Via PIPE

TLRY

Tilray Brands' 10 Barrel Brewing Unveils NA Apocalypse IPA, Offering Bold, Hop-Driven Flavor Without The Alcohol

ETSY

Etsy Q1 2025 Adj. EPS $0.46 Misses $0.49 Estimate, Sales $651.18M Beat $642.67M Estimate

Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.17 by 23.53 percent. This is a 51.85 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $2.35 billion which beat the analyst consensus estimate of $2.30 billion by 2.33 percent. This is a 14.00 percent decrease over sales of $2.73 billion the same period last year.

Dana Q1 Adj. EPS $0.13 Misses $0.17 Estimate, Sales $2.35B Beat $2.30B Estimate

Leerink Partners analyst Puneet Souda downgrades NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) from Outperform to Market Perform and lowers the price target from $25 to $9.

Leerink Partners Downgrades NeoGenomics to Market Perform, Lowers Price Target to $9

HC Wainwright &amp; Co. analyst Yi Chen reiterates LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) with a Buy and maintains $14 price target.

LFMD

HC Wainwright & Co. Reiterates Buy on LifeMD, Maintains $14 Price Target

Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) affirms FY2025 Adj EPS guidance from $4.40-$4.60 to $4.40-$4.60 vs $4.49 analyst estimate..

Guidance

Spire Affirms FY2025 Adj EPS Guidance of $4.40-$4.60 vs $4.49 Est

<ul>
<li>Amylyx expects completion of recruitment for the LUCIDITY trial in 2025, with topline data in first half of 2026</li>
<li>Pivotal Phase 3 LUCIDITY trial evaluating avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation and Orphan Drug Designation; FDA-agreed-upon primary outcome of reduction in hypoglycemic events</li>
<li>Avexitide has been previously evaluated in five post-bariatric hypoglycemia (PBH) clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant reductions in hypoglycemic events</li>
<li>The Company continues to expect cash runway through the end of 2026</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amylyx.com%2F&amp;esheet=54246224&amp;newsitemid=20250429337166&amp;lan=en-US&amp;anchor=Amylyx+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=4a42d2ccab20c0ba32567d801f80a9bc">Amylyx Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) ("Amylyx" or the "Company") today announced that the first participant has been dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric hypoglycemia (PBH).

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Pharma Announces First Participant Dosed In Pivotal Phase 3 LUCIDITY Clinical Trial Of Avexitide For Treatment Of Post-bariatric Hypoglycemia

XPRO

Expro Group Holdings Says 'Consistent with our fourth quarter earnings call, our view remains that we will continue to make progress in 2025 toward our medium-term target of mid-20s Adjusted EBITDA margin, notwithstanding near-term uncertainty related to tariffs, additional OPEC+ supply, and a range of geopolitical risks'

<ul>
<li>Statistically significant efficacy in biomarker subgroup analyses was observed:</li>
<li>&nbsp;
<ul>
<li>78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup</li>
<li>61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase (MPO) subgroup</li>
<li>90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low PD-L1 combined positive score (CPS) subgroup</li>
</ul>
</li>
<li>The biomarkers identified in the Phase 2 study are planned to be used for patient selection in the next Phase 2b study</li>
</ul>

PPBT

Purple Biotech's CM24 Shows Up To 90% Reduction In Death Risk In Pancreatic Cancer Patients, Biomarker Insights To Drive Next Phase 2b Study

Stock Split

LITM

Snow Lake Resources Announces 1-for-13 Reverse Stock Split, Will Become Effective May 2

Small Cap

Press Releases

NUTEX HEALTH REPORTS THIRD QUARTER AND YEAR TO DATE SEPTEMBER 30, 2024 FINANCIAL RESULTS

NUTEX HEALTH OPENS MILWAUKEE ER & HOSPITAL, ITS SECOND LOCATION IN WISCONSIN

NUTEX HEALTH TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

NUTEX HEALTH OPENS STARKEY RANCH ER & HOSPITAL, ITS FIRST HOSPITAL IN FLORIDA

Nutex Health Hospitals Earn Multiple Community Honors and Awards in Q4

Nutex Health Issues No Surprises Act (NSA) Arbitration Update

NUTEX HEALTH SCHEDULES 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

Nutex Health to Present at the EDPMA Solutions Summit 2025

NUTEX HEALTH RESCHEDULES EARNINGS RELEASE AND CONFERENCE CALL

NUTEX HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Biodesix

Basel Medical Group Ltd - ordinary shares

Basel Medical Group

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

DocGo

Enhabit

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

National Research Corporation - Common Stock

National Research

OPKO Health

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

Premier

Pennant Gr

Talkspace

Maxim Group

Benchmark

<a href="https://www.benzinga.com/government/regulations/25/04/45015276/wall-street-rally-pauses-tesla-heads-for-strongest-week-in-6-months-whats-driving-markets-friday" target="_blank" rel="noopener">지난주</a> 시장은 월요일(21일)의 우려스러운 하락 이후 랠리를 시도했다. 금요일(25일) S&amp;P 500 지수는 도널드 트럼프 대통령이 상호관세 부과를 <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty" target="_blank" rel="noopener">90일간 유예한다고 발표</a>한 이후 처음으로 5,500포인트 이상으로 마감했다.
벤치마크 S&amp;P 500 지수는 여전히 관세 발표 전 수준보다 150포인트 낮았지만, 투자자들은 가장 가파른 수입세가 인하되거나 완전히 무효화될 것이라는 확신을 얻고 있다.
이번 주의 불안한 출발을 감안할 때 약세장이 끝났다고 말하기에는 아직 이르다. 하지만 단기 모멘텀이 형성되고 있는 종목을 찾기 시작하기에 좋은 시기로 보인다.
오늘은 유망한 기술적 추세가 주가 상승을 이끌고 있는 6가지 종목을 살펴보려고 한다. 벤징가 엣지에서 모멘텀 점수가 최소 98점 이상인 종목 중 향후 몇 주 동안 상승할 가능성이 있는 종목에 초점을 맞추고 있다.
<h3 class="wp-block-heading">리제티 컴퓨팅 (Rigetti Computing Inc.)</h3>
벤징가 엣지 모멘텀 점수: 99.86
양자 컴퓨팅 주식은 2025년의 첫 주요 투자 트렌드 중 하나였으며, 리제티 컴퓨팅(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)은 양자 컴퓨터와 초전도 프로세서를 제조하는 가장 저명한 수혜자 중 하나였다. 이 회사의 주가는 추수감사절 무렵 1.50달러 미만으로 거래되다가 1월 첫째 주에 주가가 20달러를 돌파하는 포물선 상승세를 보였다. 기하급수적인 랠리는 얼마 지나지 않아 사라졌지만, 주가는 여전히 추수감사절 이전 평균을 훨씬 상회하고 있으며 다음 상승을 위해 준비하고 있을 수 있다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXe56O1M3JQtasNTb3WpvSiFw9pcXN0K8637FvovhUiDDeja3dnylTb7ZTfXUv8MqKCS_4vw8PP_eZWTXcFDMOVP5FercsbsgG5wAwgqx-I0mCkMosvYfOCKXVBLInT9hyEtdKAV?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
리제티 주가는 3월 초부터 좁은 박스권에서 거래되었으며, 7.50달러 수준에서 지지선을 찾은 것으로 보이며 이중 바닥이 형성될 가능성이 있다. 또 다른 단기 강세 신호는 지수이동평균(EMA)으로, 단순이동평균(SMA)보다 최근 가격을 더 중시하는 지수이동평균에서 나온다. 지난 주 5일 EMA가 10일을 넘어섰고 이후 주가는 4일 연속 상승했다. 리제티는 5월 8일에 실적을 발표할 예정인데, 이는 이미 상승 추세의 기술적 신호를 보이고 있는 주식에 또 다른 촉매제가 될 수 있다.
<h3 class="wp-block-heading">뉴텍스 헬스(Nutex Health Inc.)</h3>
벤징가 엣지 모멘텀 점수: 99.94
뉴텍스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>)는 소규모 병원 및 외래 환자 센터와 같은 의료 시설을 소유하고 있는 소규모 의료 서비스 회사다. 또한 청구, 인사, 회계 및 법률을 위한 클라우드 기반 서비스를 제공한다. 뉴텍스 주가는 4월 초에 분기 매출이 2억 5,700만 달러로 200% 이상의 어닝 서프라이즈를 기록했다는 깜짝 실적 발표 이후 수년 만에 최고치로 치솟았다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXclVzIbQdIn5Axi1ozMV6mi-C491wLKfxoi0hHHSSiAefuv8GmPqC7Hfkw3-2OwF3hzaColAPeKHXkrwIAoJtt32G16RnXRSgm3sek_CEfx1xFh13suTv1OtichKW1dlIEg9p8y4g?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
뉴텍스 주가는 이 돌파 이전부터 유망한 신호를 보였다. 50일 이평선이 9월에 200일 이평선을 넘어섰고, 이는 골든 크로스로 알려져 있으며 이후 주가의 지지선 역할을 해왔다. 그러나 주가는 빠르게 과매수되었고 상대강도지수(RSI)의 매도 신호와 함께 수일 연속 하락세를 보였다. 그러나 상승 추세는 여전히 유지되고 있으며 RSI는 과매수 트리거 지점인 70 아래로 돌아갔다. 50일 SMA가 과거 지지선 역할을 했던 것을 기억하며 이를 주시하자.
<h3 class="wp-block-heading">로켓랩 USA(Rocket Lab USA Inc.)</h3>
벤징가 엣지 모멘텀 점수: 99.46
로켓랩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)은 뉴트론(Neutron) 및 일렉트론(Electron) 발사체와 프로톤(Photon) 위성 시스템이라는 세 가지 제품군을 통해 우주선을 제작하고 발사한다. 로켓랩은 민간 및 상업용 서비스를 제공하며 여러 물체를 궤도에 올려놓았다. 주가는 10월에 수년간의 박스권에서 벗어나 1월에 사상 최고치를 경신하며 3개월 만에 200% 이상의 상승률을 달성했다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXcc_nDaxh2ONdoH7w47EIXu0Eqz2ob_EYCEartuib7DtFw0jKjWVcRVX6gfClq8gCO2odgRq3rMdCRsF10mGfpdFbs8oNLHPFYEP6bByXINpLhMbpuDZHWroOEcljeV9k6DZSdNIA?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
그러나 로켓랩 주가는 2025년에도 주당 20달러 아래로 떨어지며 좁은 박스권에서 약세를 보였다. 주가는 2월에 50일 이평선 아래로 떨어졌지만 최근 두 달 만에 50일 이평선을 돌파하며 모멘텀을 되찾았다. RSI는 과매수 임계치 아래에 머물러 있어 이 돌파가 앞으로 강세를 보일 수 있음을 나타낸다.
<h3 class="wp-block-heading">브이넷 그룹 (VNet Group Inc.)</h3>
벤징가 엣지 모멘텀 점수: 98.58
브이넷 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>)은 는 베이징과 상하이 지역에 데이터 센터를 운영하고 있으며 알리바바, 텐센트와 같은 유명 기업을 고객으로 보유하고 있다. 로켓랩과 마찬가지로 브이넷의 주가는 올해 초 포물선을 그리며 폭등했다가 다시 하락했다. 주가는 15.34달러까지 올랐다가 이달 초 다시 5달러 아래로 떨어졌다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXdCPwVUxMm9-TxlGnv_zAiMpcbcbf8C3wID2nu_pYphfsXKqMuxPL8gLVgWuZrjGVRTlT3-nLBaZgbXMUr-boP4Bby_ipGA1karSutrStrTJS0YTFha7NzZf_cNKvzornxqWzq_?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
하지만 기술적 신호가 반전을 가리키고 있기 때문에 이러한 매도세는 과도할 수 있다. RSI는 4월 들어 여러 차례 30 아래로 하락하며 과매도 상태를 나타낸다. 또한 주가는 5일 및 10일 이평선 아래에서 거래되었지만 이 두 수치 사이의 격차가 좁혀지고 있으며 현재 주가는 5일 이평선을 상회하고 있다. 5일 이평선이 10일 이평선 위로 교차하면 또 다른 상승 신호가 발생하며, 2개월간의 하락 추세가 빠르게 반전될 수 있다.
<h3 class="wp-block-heading">할라도르 에너지 (Hallador Energy Co.)</h3>
벤징가 엣지 모멘텀 점수: 98.40
인디애나에서 석탄을 채굴하는 할라도르 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>)를 예로 들어 5일 EMA가 10일 EMA를 돌파한 후 상승한 사례를 살펴볼 수 있다. 할라도르는 트럼프 행정부의 석탄에 대한 새로운 관심으로 순풍을 맞고 있으며, 주가 상승을 가리키는 몇 가지 기술적 패턴도 있다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXd38x_XWW-XIPvF_Xynv-k2JtCVRWfoZ_CqOcx743I0aXv6o0vElzNsDsKAY-OwI9qVXh-Ls8e3MerzGRcQmtXbt2KC1bbq6saNL5pvblzoUAFi4ucDida6g5DnWyUouXeCdihl?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
주가는 지난 3개월 동안 이미 50% 이상 올랐고, 5일/10일 EMA 교차는 3주 만에 주가를 11달러에서 14.69달러로 끌어올리며 또 다른 대규모 녹색 캔들을 예고했다. 주가는 5일 및 10일 이평선 위에서 거래되고 있고 RSI는 아직 과매수 영역에 있지 않기 때문에 강세 모멘텀은 여전히 유지되고 있다.
<h3 class="wp-block-heading">아처 에비에이션 (Archer Aviation Inc.)</h3>
벤징가 엣지 모멘텀 점수: 98.61
아처 에비에이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>)은 최근 두 달 만에 3.21달러에서 11.51달러로 급등했다가 이달 초 다시 7달러 이하로 떨어지는 등 격동의 시기를 보냈다. 목록에 있는 대부분의 주식과 마찬가지로 아처 주가는 최근 상당한 상승 추세가 멈췄고 이제 턴어라운드 조짐을 보이고 있다.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXd925p-JDONF6Q-L1JYUVOTTHsM2qifLuhVsLGChjiK1fIlc8FXN4U2Z_pbQLZPFovxyga52hs2rT2-5qprLq0ZL5SBThsy1HuyJlfMU9aK-XDsKjZLftvQq_VZwaDv2OKdk_NV1A?key=BFT1P88ZKYnvATe0GLA-uBhm" alt="" /></figure>
아처 주가는 몇 주 동안 하락세를 보였으나 최근 2월 중순부터 이어진 하락 추세선을 돌파하며 침체에서 벗어났다. 상승 크로스오버는 MACD에서 이 돌파를 동반했으며, 이는 이 돌파가 합법적이라는 것을 뒷받침한다. 이러한 움직임의 잠재적 촉매제는 4월 21일 니덤의 매수 의견 재확인이며, 목표주가는 13달러로 51% 이상 상승 여력을 나타냈다.
&#x2A;전문가 기고자의 콘텐츠는 일반 대중을 위한 정보로, 개별화된 투자 조언이 아닙니다. 편집자/기고자는 개인적인 의견과 전략을 제시하며, 벤징가는 이에 대해 명시적이거나 묵시적으로 승인하거나 지지하지 않습니다.
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Nutex Health

뉴스

에 대한 최신 뉴스 Nutex Health (NASDAQ:NUTX) 주식

수요일, 4월 30, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌